Jake Elguicze
Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024.
Highest-materiality recent filing
Embecta Q3 FY26 revenue down 8.1% to $271.7M; adjusted EPS $0.56 vs $1.12
Reported revenue $271.7M, down 8.1% YoY; US down 24.6%, International up 11.5%.
Embecta files Owen Mumford FY2025 audited financials; revenue £68.6M, net profit £1.68M
Owen Mumford FY2025 (Sep 30) revenue £68.6M, gross profit £33.1M, operating loss £825K.
Embecta completes acquisition of Owen Mumford for £100M upfront plus up to £50M earnout
Acquisition completed May 15, 2026; Owen Mumford is a UK-based medical device and drug-delivery technology manufacturer.
Embecta Q2 revenue drops 14.4%; FY2026 guidance cut sharply; dividend slashed to $0.01
Revenue $221.8M, -14.4% YoY; US -29.4%, Intl +2.1%; pen needles -17.8%.
Embecta to acquire Owen Mumford for up to £150M; adds drug-delivery platform
Upfront cash payment of £100M at closing; up to £50M earnout based on Aidaptus net sales by end of 2028.
Embecta Q1 FY2026 revenue $261.2M, net income $44.1M, EPS $0.74; maintains guidance
Reported revenues $261.2M, down 0.3% YoY; adjusted constant currency revenue declined 2.0%.
Embecta Q4 rev down 7.7% to $264M, net income $26.4M; FY2026 adj EPS guide $2.80-3.00
Q4 FY2025 revenue $264.0M (-7.7% YoY); GAAP net income $26.4M ($0.45 diluted EPS), up from $14.6M.
Embecta Q3 revenue up 8.4% to $295.5M; raises FY2025 guidance
Adjusted EPS $1.12 vs $0.74 prior year; reported EPS $0.78.
Reaffirmed FY2025 guidance: revenue $1.073-1.090B, adjusted EPS $2.70-$2.90, adjusted gross margin 62.75%-63.75%.
Revenue $259M, down 9.8% reported and 7.7% adjusted constant currency; U.S. -8.4%, International -7.0%.
Embecta Q1 revenue down 5.6% to $261.9M; net income nil; adj. EPS $0.65
Revenue $261.9M (-5.6% reported, -4.8% constant currency); U.S. down 4.6%, international down 5.1% constant currency.
Q4 reported rev $286.1M (+1.5%), GAAP EPS $0.25, adjusted EPS $0.45.
Embecta Q3 revenues down 4.8%; adjusted EPS up, guidance raised
Q3 revenues $272.5M, down 4.8% YoY; U.S. down 6.7%, international down 2.5% reported.
Embecta Q2 revenue up 3.6% to $287.2M; raises FY2024 guidance above prior range
Revenue of $287.2M (+3.6% reported, +4.5% constant currency); U.S. +0.8%, International +6.8%.
Embecta Q1 revenue $277.3M, adj EPS $0.61; raises FY2024 guidance
Revenue $277.3M (+0.6% reported; -0.3% constant currency); U.S. revenue down 0.5%, international up 1.8%.
Embecta Q4 revenue $281.9M (+2.7%); guides FY2024 revenue down 1-3%
Q4 GAAP EPS $0.10, adjusted EPS $0.59; full-year adjusted EPS $2.99.
Embecta Q3 revenue $286.1M (-1.7%); raises FY2023 adj. EPS guidance to $2.75-$2.80
Q3 adjusted EPS $0.69 vs. $1.07 prior year; net income $15.2M, down from $62.4M.
Embecta beats Q2 with $277M revenue (+4% CC); raises FY2023 adj EPS guidance to $2.50-$2.60
Q2 revenue $277.1M, +4.0% constant currency; US +3.6%, international +4.4% constant currency.
Embecta Q1 FY2023 adj. EPS $0.96 beats; raises full-year guidance
Revenue $275.7M, down 4.7% reported, up 0.7% constant currency.
Embecta reports Q4 FY2022 net loss $17.2M; FY2023 guidance revenue $1,050-$1,073M
Q4 revenue $274.6M, down 8.7% reported; net loss $17.2M vs income $97.1M prior year, includes $58.9M impairment.
Embecta Q3 revenue $291.1M, net income $62.4M; raises H2 FY2022 margin guidance
Revenue $291.1M (-1.3% reported, +2.0% constant currency); US +4.1%, international -7.1%.
Embecta Q2 revenue $274.5M (-3.4% reported); guides H2 FY22 revenue ~$555M (-7% YoY)
Revenue $274.5M, down 3.4% reported (-1.3% constant currency); US -5.8%, international +3.6% constant currency.
Embecta completes spin-off from BD, lists on NASDAQ as EMBC with $1.65B in new debt
Spin-off effective April 1, 2022; shares distributed to BD stockholders; EMBC listed on Nasdaq.
Embecta expands board, approves stock split and share increase for BD spin-off
Appointed Robert J. Hombach to board, increasing size from 3 to 4; Hombach also joins Audit Committee.
Embecta discloses spin-off pro forma: $1.65B debt, $1.44B distribution to BD
Spin-off of 100% Embecta shares to BD shareholders at 1:5 ratio; distribution date April 1, 2022.
Embecta sets April 1 spin-off from BD; issues $500M senior secured notes due 2030
BD to distribute 1 Embecta share for every 5 BD shares held on March 22, 2022; distribution expected April 1, 2022.
Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024.
appointed Anthony Roth as Vice President, Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024.
On August 7, 2024, Brian Capone notified Embecta Corp. (the “Company”) of his resignation as Chief Accounting Officer of the Company (“CAO”) and principal accounting officer of the Company (“PAO”), to be effective as of August 12, 2024, in order to pursue another opportunity.
Effective as of August 12, 2024, and until such time as a replacement is named, Jake Elguicze, the Chief Financial Officer of the Company (“CFO”) and principal financial officer of the Company (“PFO”), is expected to assume the role of PAO on an interim basis.
On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (“CHRO”) of Embecta Corp. (the “Company”), and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO , effective July 16, 2023.
Ajay Kumar Senior Vice President and Chief Human Resources Officer
Each of Devdatt Kurdikar, David F. Melcher, David J. Albritton, Carrie L. Anderson, Robert J. Hombach, Milton M. Morris, Claire Pomeroy, Karen N. Prange and Christopher R. Reidy was appointed as a director of Embecta as of immediately prior to the Effective Time
Brian Capone Vice President, Chief Accounting Officer and Corporate Controller
Each of Devdatt Kurdikar, David F. Melcher, David J. Albritton, Carrie L. Anderson, Robert J. Hombach, Milton M. Morris, Claire Pomeroy, Karen N. Prange and Christopher R. Reidy was appointed as a director of Embecta as of immediately prior to the Effective Time
Devdatt Kurdikar President and Chief Executive Officer
Each of Devdatt Kurdikar, David F. Melcher, David J. Albritton, Carrie L. Anderson, Robert J. Hombach, Milton M. Morris, Claire Pomeroy, Karen N. Prange and Christopher R. Reidy was appointed as a director of Embecta as of immediately prior to the Effective Time
Gary DeFazio, Joseph LaSala and Stephanie Kelly, who had been serving as members of the Board as of immediately prior to the Effective Time, ceased to be directors of Embecta.
Max materiality 0.85 · Median 0.70 · Most common event earnings